Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.

ABSTRACT:

Importance

Immune checkpoint inhibitors (ICIs) have transformed the survival of patients with metastatic melanoma. Patient prognosis is reflected by the American Joint Committee on Cancer (AJCC) staging system; however, it is unknown whether the metastatic (M) stage categories for cutaneous melanoma remain informative of prognosis in patients who have received ICIs.

Objectives

To evaluate the outcomes of patients with metastatic cutaneous melanoma based on the M stage category from the AJCC eighth edition and to determine whether these designations continue to inform the prognosis of patients who have received ICIs.

Design, setting, and participants

This cohort study included patients with metastatic cutaneous melanoma who were treated between August 2006 and August 2

SUBMITTER: Waninger JJ 

PROVIDER: S-EPMC7944385 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature